Trials / Terminated
TerminatedNCT01121588
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
PHASE 1B OPEN-LABEL STUDY OF THE SAFETY AND CLINICAL ACTIVITY OF CRIZOTINIB (PF-02341066) IN TUMORS WITH GENETIC EVENTS INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK ) GENE LOCUS
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 1 trial evaluating the safety and efficacy of crizotinib in patients with tumors except non-small cell lung cancer that are positive for ALK.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Crizotinib | Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule |
Timeline
- Start date
- 2011-03-22
- Primary completion
- 2023-09-07
- Completion
- 2023-09-07
- First posted
- 2010-05-12
- Last updated
- 2025-01-23
- Results posted
- 2025-01-23
Locations
21 sites across 7 countries: United States, China, Italy, Japan, Russia, South Korea, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01121588. Inclusion in this directory is not an endorsement.